Track topics on Twitter Track topics that are important to you
Donor Umbilical Cord Blood Transplant In Treating Patients With Advanced Hematologic Cancer PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Donor Umbilical Cord Blood Transplant In Treating Patients With Advanced Hematologic Cancer articles that have been published worldwide.
We have published hundreds of Donor Umbilical Cord Blood Transplant In Treating Patients With Advanced Hematologic Cancer news stories on BioPortfolio along with dozens of Donor Umbilical Cord Blood Transplant In Treating Patients With Advanced Hematologic Cancer Clinical Trials and PubMed Articles about Donor Umbilical Cord Blood Transplant In Treating Patients With Advanced Hematologic Cancer for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Donor Umbilical Cord Blood Transplant In Treating Patients With Advanced Hematologic Cancer Companies in our database. You can also find out about relevant Donor Umbilical Cord Blood Transplant In Treating Patients With Advanced Hematologic Cancer Drugs and Medications on this site too.
We previously demonstrated a lower rate of CMV reactivation and disease among seropositive umbilical cord blood transplant (CBT) recipients receiving an intensive prophylaxis strategy consisting of ganciclovir on days -8 to -2 pre-transplant, high-dose valacyclovir post-transplant, and twice-weekly serum CMV PCR testing. We hypothesized that a modified intensive strategy excluding pre-transplant ganciclovir would be similarly effective. We compared the risk of CMV reactivation, occurrence of CMV disease, an...
Recently, haplo-identical transplantation (haplo) using post-transplant cyclophosphamide (PTCy) has been reported to give very encouraging results in patients with hematological malignancies. Patients who have no HLA-matched donor currently have the choice between a mismatched unrelated donor, an unrelated cord blood donor and a haplo-identical related donor. The aim of our study is to compare the outcome of patients with myelodysplastic syndrome (MDS) who have been transplanted from a haplo-identical donor...
Hematopoietic stem cell transplant (HSCT) with matched sibling donor (MSD) is considered the first line of therapy for patients with severe aplastic anemia (SAA) who are
Umbilical cord blood transplantation (UCBT) is a possible option for aplastic anemia (AA) patients without a related or unrelated human leukocyte antigen-matched donor, particularly if immunosuppressive therapy (IST) has failed, or an urgent transplant is needed. However, a higher rate of graft failure after UCBT remains a major problem, and the optimal conditioning regimen for stable engraftment after UCBT has not been established. Here, we investigated six adult AA patients who underwent UCBT using a redu...
Traditional validation of umbilical cord blood samples with positive veno-arterial (V-A) ΔpH and A-V ΔpCO values confirms the source of samples, where negative Δvalues represent mix-up of samples. To investigate whether this is true, the distributions of V-A ΔpO and A-V Δlactate were also explored and related to clinical characteristics. In addition, different cord blood sampling techniques were evaluated MATERIAL AND METHODS: Register study with cord blood acid-base and clinical data from 27 233 newbo...
To evaluate the implementation of an institutional protocol for universal delayed umbilical cord clamping (DCC) at term on maternal, neonatal, and umbilical cord blood gas outcomes.
Donor-specific human leukocyte antigen (HLA) antibodies are a significant risk factor for graft failure in cord blood transplantation (CBT). Although there are several treatments to decrease HLA antibodies, such as platelet transfusion, plasma exchange, rituximab, and bortezomib, their effectiveness has not been established.
Previous studies have reported the use of cord blood for admission laboratory complete blood counts (CBCs). However, no studies have investigated its stability for the first 30 min after delivery.
To explore the clinical efficacy and safety of unrelated umbilical cord blood transplantation (UCBT) in the treatment of refractory and relapsed acute leukemia (AL) patients.The clinical data of 22 refractory and relapsed AL patients who were treated with UCBT as salvage therapy from November 2009 to May 2017 were retrospectively analyzed. All patients received a myeloablative conditioning regimen for prevention of graft-versus-host disease (GVHD) with cyclosporine A (CSA)/short course of mycophenolate mofe...
Preeclampsia is the most common disorder associated with pregnancy. Our earlier findings revealed a substantial increase in the amount of matrix metalloproteinase-26 (matrilysin 2; MMP-26) in preeclamptic umbilical cord blood. The role of MMP-26 in preeclamptic umbilical cord tissue has not been fully elucidated. Some reports have indicated that the expression of matrilysin 2 and tissue inhibitor of matrix metalloproteinase 4 (TIMP-4) is coordinately regulated during progression of various diseases.
Hematopoietic stem cell transplantation is considered the only curative therapy for very early-onset inflammatory bowel disease with specific immune defects, such as interleukin-10 receptor deficiency. We performed reduced-intensity conditioning before umbilical cord blood transplantation in patients with interleukin-10 receptor-A deficiency.
Although umbilical cord blood gas analysis is considered the best way to assess in utero oxygenation in human neonates, there is limited evaluation of this method in equine neonatology. Our objectives were to assess the practicality of obtaining umbilical cord blood gas samples in the field and to determine umbilical cord arterial and venous blood gas reference intervals (RI) for healthy, newborn foals. Thoroughbred foals >320 days gestation from healthy mares with uneventful pregnancies at one stud farm we...
The aim is to obtain normal newborn umbilical cord diameters for use it in the evaluation of congenital umbilical hernia.
As deceased donor kidney allocation is based in part on blood type compatibility, group B candidates are disadvantaged due to their disproportionate representation on the wait list compared to the group B donor pool. To mitigate this discrepancy, group B candidates can receive group A or A B donor kidneys if their anti-A titers are below a predetermined cutoff. Currently, eligibility is reverified quarterly to UNet based on individual center protocols, which can vary due to a lack of set guidelines for moni...
Allogeneic stem cell transplantation is an alternative for patients with relapsed or refractory Hodgkin lymphoma (HL) but only limited data on unrelated umbilical cord blood transplantation (UCBT) are available. We analyzed 131 adults with HL who underwent UCBT in EBMT centers from 2003 to 2015. Disease status at UCBT was complete remission (CR) in 59 (47%) and almost all patients had received a previous autologous stem cell transplantation. The 4-year PFS and OS were 26% (95% CI 19-34%) and 46% (95% CI 37-...
No validated biomarker at birth exists to predict which newborns will develop severe hyperbilirubinemia. This study's primary aim was to build and validate a prediction model for severe hyperbilirubinemia using umbilical cord blood bilirubins (CBB) and risk factors at birth in neonates at risk for maternal-fetal blood group incompatibility. This study's secondary aim was to compare the accuracy of CBB to the direct antigen titer.
To investigate the effect of intracavernous injection of human umbilical cord blood derived endothelial colony forming cells (HUCB ECFCs) on erectile dysfunction (ED) in Zucker Diabetic Fatty (ZDF) rat model.
ABO-incompatible (ABOi) hematopoietic stem cell transplants (HSCTs) can present challenges in the blood bank. During transplantation, patients receive components that are ABO-compatible with both the donor graft and recipient; this practice can strain group O red blood cell (RBC) inventories.1 In addition, there are risks for acute hemolysis at the time of infusion and in the early post-transplant period.1,2 In ABO major-incompatible bone marrow HSCTs, which contain significant quantities of donor RBCs that...
This study was designed to evaluate umbilical cord ischaemia-modified albumin (IMA) levels and the cord blood gas parameters of foetuses with or without nuchal cords, at the time of elective C-section. The cross-sectional study population consisted of the patients who were admitted to the Tertiary Care Center between February and June 2015. Women with uncomplicated single term gestations between 37 and 40 completed weeks and scheduled for elective C-sections were included in the study. Fifty cases with a nu...
Optimum timing of umbilical cord clamping has not been established in preterm infants.
Relapse following allogeneic hematopoietic cell transplantation (HCT) for acute leukemia can be reduced when pursued early after first complete remission. The impact of donor age and donor relatedness on the time from diagnosis to transplant in patients with acute leukemia was examined to clarify the design of future prospective studies that can address optimal donor choice. Files of 100 consecutive patients undergoing transplantation for leukemia were reviewed. Recipients of related (RD) and unrelated dono...
Allocation to matched-related or unrelated donor results in similar clinical outcomes without increased risk of failure to proceed to transplant among patients with acute myeloid leukemia: a retrospective analysis from the time of transplant approval.
Clinical outcomes after allogeneic hematopoietic stem cell transplantation (allo-SCT) from unrelated donors (URD) approach those of matched-related donor (MRD) transplants in patients with acute myeloid leukemia (AML). Yet, available data fail to account for differences in pre-transplantation outcomes between these donor selection strategies. In this regard, URD allo-SCT is associated with longer waiting times to transplantation, potentially resulting in higher probabilities of failure to reach transplant. ...
Herein, we measured the concentration of insulinlike growth factor I (IGF-I), IGF-II, leptin, adiponectin, ghrelin, resistin, and visfatin in the umbilical cord blood of newborns categorized as "small for gestational age" (SGA), "appropriate for gestational age" (AGA), and "large for gestational age" (LGA). Our aim was to elucidate the link between the levels of these proteins and fetal growth.
Minimizing initial neonatal blood draws and their associated pain is important. The placenta has ample fetal blood that is otherwise discarded; obtaining admission laboratory evaluations from fetal umbilical venous blood (FUVB) may provide a suitable alternative.
Infants born preterm following exposure to in utero inflammation/chorioamnionitis are at high risk of brain injury and life-long neurological deficits. In this study, we assessed the efficacy of early intervention umbilical cord blood (UCB) cell therapy in a large animal model of preterm brain inflammation and injury. We hypothesised that UCB treatment would be neuroprotective for the preterm brain following subclinical fetal inflammation.